select a format

Single User License
USD 250 INR 16073
Site License
USD 500 INR 32145
Corporate User License
USD 750 INR 48218

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


RedHill Biopharma Ltd (RDHL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

RedHill Biopharma Ltd (RDHL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH246971D
  • |
  • Pages: 104
  • |
  • August 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

RedHill Biopharma Ltd (RedHill) is a biopharmaceutical company that develops and commercializes small molecule therapeutics in the areas of gastroenterology, oncology and inflammation. The company's commercial product portfolio consists of gastrointestinal therapeutics for acute enterocolitis and irritable bowel syndrome (IBS), and chronic diarrhea and loose stools. It is investigating its pipeline candidates for the treatment of gastrointestinal and inflammatory diseases that include helicobacter pylori infection, crohn's disease, multiple sclerosis, pancreatic cancer, and migraine. RedHill works in collaboration with various pharmaceutical companies to in-license and commercialize its products in the US. The company has offices in Israel and the US. RedHill is headquartered in Tel Aviv, Israel.

RedHill Biopharma Ltd (RDHL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

RedHill Biopharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

RedHill Biopharma Extends Option Agreement to Acquire RP-101 from RESprotect 13

Partnerships 14

RedHill Biopharma Enters into Research Agreement with Aarhus University 14

Concordia International Enters into Co-Promotion Agreement with RedHill Biopharma 15

RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 16

RedHill Biopharma Enters into Agreement with NIAID 17

RedHill Biopharma Enters into Research Agreement with Fraunhofer Institute for RP101 18

Licensing Agreements 19

RedHill BioPharma Enters into Licensing Agreement with Entera Health 19

IntelGenx and RedHill Biopharma Enter into Licensing Agreement with Pharmatronic 20

RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 21

Grupo Juste to Enter into Licensing Agreement with RedHill Biopharma and IntelGenx 22

RedHill Biopharma Enters into Licensing Agreement with Apogee Biotech 23

RedHill Biopharma Enters into Licensing Agreement with University of Minnesota 25

Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 26

RedHill Biopharma Signs Memorandum Of Understanding With IntelGenx Technologies For RHB-103 27

Equity Offering 28

RedHill Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADSs and Warrants for USD39.4 Million 28

RedHill Biopharma Withdraws Public Offering of ADSs 30

RedHill Biopharma Raises USD40 Million in Public Offering of American Depository Shares 31

RedHill Biopharma Completes Exercise of Underwriter's Over Allotment Option for Public Offering of ADSs for USD14.4 Million 33

RedHill Biopharma Raises USD12.5 Million in Public Offering of American Depository Shares 35

RedHill Biopharma Completes Private Placement Of Shares And Warrants For USD11.7 Million 36

RedHill Biopharma Completes Private Placement Of Units For USD8.5 Million 38

RedHill Biopharma Completes Private Placement Of Shares For USD7 Million 40

RedHill Biopharma Completes IPO Of Units For USD13.6 Million 41

RedHill Biopharma Ltd-Key Competitors 43

RedHill Biopharma Ltd-Key Employees 44

RedHill Biopharma Ltd-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Recent Developments 46

Financial Announcements 46

Jul 25, 2017: RedHill Biopharma Reports 2017 Second Quarter Financial Results 46

May 03, 2017: RedHill Biopharma Reports 2017 First Quarter Financial Results 48

Feb 23, 2017: RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results 49

Nov 14, 2016: RedHill Biopharma Reports 2016 Third Quarter Financial Results 51

Jul 26, 2016: RedHill Biopharma Reports 2016 Second Quarter Financial Results 54

Apr 20, 2016: RedHill Biopharma Reports 2016 First Quarter Financial Results 57

Feb 25, 2016: RedHill Biopharma Reports 2015 Fourth Quarter and Full-Year Financial Results 59

Corporate Communications 63

Jan 04, 2017: RedHill and Concordia sign co-promotion agreement for Donnatal drug promotion 63

Product News 64

04/19/2017: RedHill Biopharma to Host R&D Day on BEKINDA for Acute Gastroenteritis and IBS-D 64

Product Approvals 65

Feb 11, 2016: RedHill Biopharma Announces Successful PK Study with BEKINDA 12 mg and Submission to FDA of IBS-D Phase II Study Protocol 65

Clinical Trials 67

Jun 15, 2017: RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA) for H. pylori Infection 67

May 04, 2017: RedHill Biopharma Announces Poster Presentation of the Positive RHB-105 Phase III Results for H. pylori Infection at Digestive Disease Week 2017 69

Apr 24, 2017: RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D 70

Apr 18, 2017: RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA 71

Feb 21, 2017: RedHill Biopharma Completes Treatment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis 72

Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis 74

Jan 12, 2017: RedHill Biopharma Provides Milestone Update on Bekinda 76

Jan 12, 2017: RedHill Biopharma Provides Milestone Update on RHB-105 77

Jan 10, 2017: RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection 78

Jan 09, 2017: RedHill Biopharmas RHB-105 Positive Phase III Study Results for H. pylori Infection Presented at the Innovations in Gastroenterology 2017 Symposium 80

Jan 04, 2017: RedHill Biopharma to Present the Positive Results of the First Phase III study with RHB-105 for H. pylori Infection at the Innovations in Gastroenterology 2017 Symposium 81

Nov 10, 2016: RedHill Biopharma Reports Positive FDA Type B Meeting on RHB-105 for H. pylori Infection Ahead of Confirmatory Phase III Study 82

Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results 84

Jun 20, 2016: RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA for IBS-D 86

Apr 18, 2016: RedHill Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection 87

Apr 11, 2016: RedHill Biopharma Initiates Phase II Study of BEKINDA for Irritable Bowel Syndrome 89

Mar 08, 2016: RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection 90

Mar 01, 2016: RedHill Biopharma Provides Update on RHB-102 92

Mar 01, 2016: RedHill Biopharma Provides Update on RHB-105 93

Feb 10, 2016: RedHill Biopharma Receives Notice of Allowance of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program 94

Other Significant Developments 95

Aug 10, 2017: RedHill Biopharma Provides 2017 Semi-Annual Business Update 95

Mar 29, 2017: RedHill Biopharma: Notice of Annual General Meeting of Shareholders 98

Aug 11, 2016: RedHill Biopharma Provides 2016 Semi-Annual R&D Update 100

May 06, 2016: RedHill Biopharma: Notice of Annual General Meeting of Shareholders 102

Feb 09, 2016: RedHill Biopharma Issues Letter to Shareholders 103

Appendix 104

Methodology 104

About GlobalData 104

Contact Us 104

Disclaimer 104

List of Figures

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

RedHill Biopharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

RedHill Biopharma Ltd, Deals By Therapy Area, 2011 to YTD 2017 9

RedHill Biopharma Ltd, Medical Devices Deals, 2011 to YTD 2017 10

RedHill Biopharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

RedHill Biopharma Extends Option Agreement to Acquire RP-101 from RESprotect 13

RedHill Biopharma Enters into Research Agreement with Aarhus University 14

Concordia International Enters into Co-Promotion Agreement with RedHill Biopharma 15

RedHill Biopharma Enters into Research Agreement with Stanford University School of Medicine 16

RedHill Biopharma Enters into Agreement with NIAID 17

RedHill Biopharma Enters into Research Agreement with Fraunhofer Institute for RP101 18

RedHill BioPharma Enters into Licensing Agreement with Entera Health 19

IntelGenx and RedHill Biopharma Enter into Licensing Agreement with Pharmatronic 20

RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 21

Grupo Juste to Enter into Licensing Agreement with RedHill Biopharma and IntelGenx 22

RedHill Biopharma Enters into Licensing Agreement with Apogee Biotech 23

RedHill Biopharma Enters into Licensing Agreement with University of Minnesota 25

Salix Pharma Enters Into Licensing Agreement With RedHill Biopharma For RHB-106 Encapsulated Bowel Preparation Product 26

RedHill Biopharma Signs Memorandum Of Understanding With IntelGenx Technologies For RHB-103 27

RedHill Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADSs and Warrants for USD39.4 Million 28

RedHill Biopharma Withdraws Public Offering of ADSs 30

RedHill Biopharma Raises USD40 Million in Public Offering of American Depository Shares 31

RedHill Biopharma Completes Exercise of Underwriter's Over Allotment Option for Public Offering of ADSs for USD14.4 Million 33

RedHill Biopharma Raises USD12.5 Million in Public Offering of American Depository Shares 35

RedHill Biopharma Completes Private Placement Of Shares And Warrants For USD11.7 Million 36

RedHill Biopharma Completes Private Placement Of Units For USD8.5 Million 38

RedHill Biopharma Completes Private Placement Of Shares For USD7 Million 40

RedHill Biopharma Completes IPO Of Units For USD13.6 Million 41

RedHill Biopharma Ltd, Key Competitors 43

RedHill Biopharma Ltd, Key Employees 44

RedHill Biopharma Ltd, Subsidiaries 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

RedHill Biopharma Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com